The effects of zinc supplementation on body fat mass in hemodialysis patients: An open-label randomized controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Zinc deficiency is highly prevalent in HD patients.

On the other hand, it remains unknown about the role of zinc in their nutritional status.

Who Took Part

According to the abstract, 48 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

The researchers investigated (i) the relationship between serum zinc levels and body composition and (ii) the effects of zinc supplementation on the composition of 48 HD patients with zinc deficiency.

How the Study Was Run

In design terms this was a randomized and open-label study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Being open-label, the Vitamin D, K2, Magnesium and Zinc study did not mask who received what.

The researchers conducted an open-label randomized controlled trial.

What Was Measured

The subject headings attached to it are Zinc, Renal Dialysis, Dietary Supplements, Body Composition, Adipose Tissue and Nutritional Status.

The authors tagged it with the keywords fat mass, hemodialysis, nonfat mass and zinc deficiency.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in 48 patients.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy), a journal based in Australia.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.